[go: up one dir, main page]

NO20061167L - Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon - Google Patents

Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon

Info

Publication number
NO20061167L
NO20061167L NO20061167A NO20061167A NO20061167L NO 20061167 L NO20061167 L NO 20061167L NO 20061167 A NO20061167 A NO 20061167A NO 20061167 A NO20061167 A NO 20061167A NO 20061167 L NO20061167 L NO 20061167L
Authority
NO
Norway
Prior art keywords
inhibitor
serotonin reuptake
disorders
depression
treatment
Prior art date
Application number
NO20061167A
Other languages
English (en)
Inventor
Jorn Arnt
Michael Didriksen
Sandra Hogg Willigers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20061167L publication Critical patent/NO20061167L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfirmelse vedrører anvendelsen av en forbindelse, som er en serotonin- reopptaksinhibitor, og en forbindelse, som er en GlyT-1-inhibitor for fremstillingen av en farmasøytisk sammensetning forbehandlingen av depresjon, angstiidelser og andre affektive lidelser. Spesielt vedrører den foreliggende oppfirmelse behandling av depresjon, angstlidelser og andre affektive hdelser, slik som generalisert angstlidelse, panikkangst, obsessiv-kompulsiv hdelse, akutt stresslidelse, posttraumatisk stresslidelse og sosial angstlidelse, spiseforstyrrelser slik som bulimia, anorexia og obesitet, fobier, dystymi, premenstruelt syndrom, kognitive lidelser, impulskontrolhdelser, oppmerksomhetssvikt-hyperaktivitets-syndromet, legemiddelmisbruk eller enhver armen hdelse som reagerer på serotonin-reopptaksinhibitorer. Den foreliggende oppfirmelse vedrører også en farmasøytisk sammensetning omfattende en serotonin-reopptaksinhibitor og en GlyT-1-inhibitor.
NO20061167A 2003-08-21 2006-03-13 Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon NO20061167L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49673803P 2003-08-21 2003-08-21
DKPA200301198 2003-08-21
PCT/DK2004/000547 WO2005018676A1 (en) 2003-08-21 2004-08-18 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression

Publications (1)

Publication Number Publication Date
NO20061167L true NO20061167L (no) 2006-03-13

Family

ID=34219531

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061167A NO20061167L (no) 2003-08-21 2006-03-13 Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon

Country Status (12)

Country Link
US (1) US20060223857A1 (no)
EP (1) EP1660130A1 (no)
JP (1) JP2007502785A (no)
KR (1) KR20060066729A (no)
CN (1) CN1867358A (no)
AU (1) AU2004266057A1 (no)
BR (1) BRPI0413587A (no)
CA (1) CA2536275A1 (no)
IS (1) IS8277A (no)
MX (1) MXPA06002002A (no)
NO (1) NO20061167L (no)
WO (1) WO2005018676A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402320A2 (hu) * 2001-12-20 2005-03-29 H. Lundbeck A/S Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2008100727A2 (en) * 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
PT1014966E (pt) * 1996-05-31 2006-12-29 Allelix Neuroscience Inc Composição farmacêutica para o tratamento de disturbios neurológicos e neuropsiquiátricos.
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
ES2238466T3 (es) * 2000-07-21 2005-09-01 H. Lundbeck A/S Compuestos y su uso como inhibidores del transporte de glicina.
HUP0402320A2 (hu) * 2001-12-20 2005-03-29 H. Lundbeck A/S Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CN100430063C (zh) * 2002-06-20 2008-11-05 H.隆德贝克有限公司 使用5-羟色胺再摄取抑制剂的联合药物
EA010430B1 (ru) * 2003-05-27 2008-08-29 Форест Лэборэтериз, Инк. Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств

Also Published As

Publication number Publication date
AU2004266057A1 (en) 2005-03-03
BRPI0413587A (pt) 2006-10-17
CN1867358A (zh) 2006-11-22
EP1660130A1 (en) 2006-05-31
US20060223857A1 (en) 2006-10-05
JP2007502785A (ja) 2007-02-15
KR20060066729A (ko) 2006-06-16
WO2005018676A1 (en) 2005-03-03
MXPA06002002A (es) 2006-05-17
IS8277A (is) 2006-01-31
CA2536275A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NO20100333L (no) Behandling av nevrotiske forstyrrelser
SE0301010D0 (sv) Novel compounds
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
SE0301009D0 (sv) Novel compounds
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
NO20061167L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon
NO20045552L (no) Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
NO20053810L (no) Thiofenkarboksamider som inhibitorer av enzymet IKK-2
JP2006514952A5 (no)
WO2005056056A3 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
DE502004006525D1 (de) Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen
NO20082201L (no) Stabile farmasoytiske formuleringer inneholdende escitalopram og bupropion
EA200601158A1 (ru) Комбинация ингибитора обратного захвата серотонина и антагониста, обратного агониста или частичного агониста рецептора гистамина 3
NO20051617L (no) Piperidinderivater av heterocyklusfusjonerte benzodioksaner med antidepressiv aktivitet
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
WO2007070840A3 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
EA200600453A1 (ru) Комбинация ингибитора обратного захвата серотонина и ингибитора переносчика глицина типа 1 для лечения депрессии

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104